Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Debt: 2021-2022

Historic Non-Current Debt for Autolus Therapeutics (AUTL) over the last 2 years, with Dec 2022 value amounting to $116,000.

  • Autolus Therapeutics' Non-Current Debt rose 24.35% to $342.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $342.9 million, marking a year-over-year increase of 24.35%. This contributed to the annual value of $275.2 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Autolus Therapeutics reported Non-Current Debt of $275.2 million as of FY2021.
  • Autolus Therapeutics' Non-Current Debt's 5-year high stood at $275.2 million during FY2021, with a 5-year trough of $275.2 million in FY2021.
  • Over the past 2 years, Autolus Therapeutics' median Non-Current Debt value was $122,000 (recorded in 2021), while the average stood at $122,000.
  • Data for Autolus Therapeutics' Non-Current Debt shows a maximum YoY declined of 9.38% (in 2022) over the last 5 years.
  • Over the past 2 years, Autolus Therapeutics' Non-Current Debt (Yearly) stood at $128,000 in 2021, then decreased by 9.38% to $116,000 in 2022.